A new report warned that the lack of product development in the generics and biosimilars sector could imperil billions of dollars in potential savings. The trade group’s analysis points to a risk that without sustained development activity, the economic rationale for cheaper biologic access may erode. Separately, commentary highlighted how pricing and regulatory pressures are pushing Rx companies toward more global commercialization strategies, changing launch timing and even which indications get prioritized by market.